You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023292019
Dec 20236609
Jan 20248909
Feb 20245001
Mar 20248403
Apr 20246004
May 20244403
Jun 20248106
Jul 20245803
Aug 20247803
Sep 20247405
Oct 2024134016
Nov 202410002
Dec 20249005
Jan 20257606
Feb 20252904
Mar 2025005
Apr 2025007
May 2025004
Jun 2025004
Total14050118